SCHEMBL30909224

SCHEMBL30909224

Ic1ccc2[nH]cc(C3CCN(CCc4ccccc4)CC3)c2n1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1F P30939 13/20 0.60
HTR1D P28221 11/20 0.51
HTR1B P28222 11/20 0.51
HTR1A P08908 7/20 0.48
HTR2A P28223 2/20 0.47
HTR2C P28335 2/20 0.47
DRD2 P14416 2/20 0.47
KCNH2 Q12809 1/20 0.47
OPRM1 P35372 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46
HTR1E P28566 1/20 0.44
HTR6 P50406 1/20 0.44
HTR4 Q13639 1/20 0.44
PRCP P42785 1/20 0.44
ACHE P22303 1/20 0.44
DRD4 P21917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7012310 1.00 HTR1F (0.60) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL7009425 0.87 HTR1F (0.65) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL30909044 0.83 HTR1F (0.66) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL7012121 0.80 HTR1F (0.75) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL7008438 0.80 HTR1F (0.75) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL7010340 0.79 HTR1F (0.88) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL7008169 0.78 HTR1F (0.74) HTR1FHTR1DHTR1BHTR1AHTR2A
SCHEMBL9032327 0.77 ADRA1D (0.69) HTR2AHTR2CDRD2KCNH2
Hydrochloric Acid SCHEMBL30908966 0.76 ADRA1D (0.70) HTR2AHTR2CDRD2KCNH2
SCHEMBL7010196 0.76 HTR1F (0.83) HTR1FHTR1DHTR1BHTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D HTR1F 1/4885HTR1D 3/4885HTR1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.